Public procurement notice: Prior Information Notice Without Call For Competition
Published: 2017-08-02
Buyer: Cell & Gene Therapy Amendment to Restricted OJEU Process Tender, PIN — Value estimation incorrect on original PIN Issued
Country: UK
Contract type: Works
CPV classification: 71540000: Construction management services

Technical requirements: This Is a Restricted Process. The Supply of Construction Services for the Cell Gene Therapy Manufacturing Centre Phase 2.
This is Amendment to the original PIN Estimation of Value of Works should read 9 000 000 GBP — 11 000 000 GBP.
With Phase 1 due to complete mid 2017, there is a business need to increase the number of modules within the facility from the 6nr completed as part of Phase 1 to 12nr (Phase 2).
Expressions of interest are sought from suitably qualified contractors responding to this SQ PQQ, who will need to demonstrate experience in successfully delivering the fit out of complex, GMP biologics manufacturing projects of the scale and to the programme required for this Project.
Cell & Gene Therapy intends to appoint a combined project management and design team to work with CGT to deliver the proposed Phase 2 of the Project.
— have suitable technical skills in respect of design, programming fast-track projects, coordination and integration of design and construction-related activities;
— have, together with their proposed supply chain sub-contractors and suppliers, specific expertise, experience and skills in delivering projects of a similar nature to the CGT requirement involving the design, commissioning and successful handover;
— possess an exceptional health and safety record — our requirement is reflected in the allocated weightings for the questions relating to health and safety within this SQ;
— have managed the design and construction process to deliver similar projects to at least an ‘Very Good’ BREEAM standard;
— can provide evidence of their expertise and a proven commitment to delivery within agreed programmes, costs, quality and, most importantly, focused delivery to meet client objectives.
The concept design is currently being developed but the requirement is likely to involve the following as progressed but is likely to include:
— Flexible configuration Grade C Clean room space suitable for Advanced Therapy Medicinal Product manufacture, with the ability to deliver multiple parallel processes for Autologous product manufacturing, and the flexibility to convert the clean spaces to manufacture either Allogeneic products at up to 1 000 L scale, gene modified products or regenerative organs. The clean rooms will also have the flexibility for conversion between Grade C and Grade D classifications;
— It must achieve the requisite licences for GMP manufacturing from the MHRA and be capable of meeting all regulatory requirements in significant markets worldwide, including US FDA cGMPs.
— It will be based on the Manufacturing module principle developed at the Cell and Gene Therapy Catapult with additional flexible support space.
Changes are the Estimated Value for this Restrictive Procurement Process and The adjustment only of the PQQ return date which will be adjusted in the E-Sourcing Tool being used for this tender and as advised by the Regulations when a change is made (2 weeks) will be added to the current return date.